UK's Epistem Inks Two-Year Stem-Cell Drug-Discovery Collaboration With Novartis

Under terms of the deal, Novartis will give Epistem a $4 million upfront payment and provide funding to study the stem cell shop's drug targets. Epistem could also get up to $45 million in milestone payments for each product developed from targets licensed under the agreement.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.